NovoPen Echo® insulin delivery device

Abstract

The introduction of insulin pen devices has provided easier, well-tolerated, and more convenient treatment regimens for patients with diabetes mellitus. When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses. The portable and discreet nature of pen devices reduces the burden on the patient, facilitates adherence, and subsequently contributes to the improvement in glycemic control. NovoPen Echo® is one of the latest members of the NovoPen® family that has been specifically designed for the pediatric population and is the first to combine half-unit increment (=0.5 U of insulin) dosing with a simple memory function. The half-unit increment dosing amendments and accurate injection of 0.5 U of insulin are particularly beneficial for children (and insulin-sensitive adults/elders), who often require small insulin doses. The memory function can be used to record the time and amount of the last dose, reducing the fear of double dosing or missing a dose. The memory function also provides parents with extra confidence and security that their child is taking insulin at the correct doses and times. NovoPen Echo is a lightweight, durable insulin delivery pen; it is available in two different colors, which may help to distinguish between different types of insulin, providing more confidence for both users and caregivers. Studies have demonstrated a high level of patient satisfaction, with 80% of users preferring NovoPen Echo to other pediatric insulin pens.

Patient and physician preferences for atopic dermatitis injection treatments in Japan

“…Given the strong influence of needle fear and cost on patients' preferences, physicians could seek to educate patients on the injection experience to alleviate their concerns and justify the higher treatment costs based on increased efficacy, better disease control and reduced medications in the long term. The development of future biologic treatments could also consider injection devices that are more acceptable to patients; research in diabetes shows that injection pens are associated with greater acceptance and patient adherence than syringe injections (23,24). Based on the patient characteristics associated with a preference for new injectable treatments, physicians can also target their recommendation of biologic treatments to patients who value convenience, e.g.…”

Assessment of factors determining an HbA1c concentration ≤7.5% in patients with type 1 diabetes

“…Interestingly, %TBD showed a weak correlation with TDD ( y = 0.3 x ), possibly because patients with a low TBD (especially <10 U) received higher‐than‐optimal insulin doses due to the use of prefilled injector pens. Pen injectors allow more accurate and reproducible administration of low insulin doses than syringes; however, they cannot be used to adjust the dose in small increments of, for example, 0.1 U. Thus, patients with a low TBD should consider using other devices, such an insulin pump, which would allow for more precise adjustment of the insulin dose.…”

Insulin-delivery methods for children and adolescents with type 1 diabetes

“…Insulin pens are more accurate, user friendly (with less fear of injections), and associated with low pain when used with short and fine needles. 8,9,[24][25][26] NovoPen Echo® (NovoNordisk A/S, Bagsvaerd, Denmark) has merged two features, memory function, and half-unit increments dosing. It is a user-friendly, long-lasting insulin pen tailored for the pediatric population.…”